Heesen et al. Prognostic Risk Estimates of Patients with Multiple Sclerosis and Their Physicians: Comparison to an Online Analytical Risk Counseling Tool. PLoS One. 2013 May 17;8(5):e59042. Print 2013
BACKGROUND: Prognostic counseling in MS is difficult because of the high variability of disease progression. Simultaneously, MSers and physicians are increasingly confronted with making treatment decisions at an early stage, which requires taking individual prognoses into account to strike a good balance between benefits and harms of treatments. It is therefore important to understand how MSers and physicians estimate prognostic risk, and whether and how these estimates can be improved. An online analytical processing (OLAP) tool based on pooled data from placebo cohorts of clinical trials offers short-term prognostic estimates that can be used for individual risk counseling.
OBJECTIVE: The aim of this study was to clarify if personalized prognostic information as presented by the OLAP tool is considered useful and meaningful by MSers. Furthermore, they used the OLAP tool to evaluate MSers’ and physicians’ risk estimates. Within this evaluation process they assessed short-time prognostic risk estimates of MSers (final n = 110) and their physicians (n = 6) and compared them with the estimates of OLAP.
RESULTS: MSers rated the OLAP tool as understandable and acceptable, but to be only of moderate interest. It turned out that MSers, physicians, and the OLAP tool ranked MSers similarly regarding their risk of disease progression. Both MSers’ and physicians’ estimates correlated most strongly with those disease covariates that the OLAP tool’s estimates also correlated with most strongly. Exposure to the OLAP tool did not change MSers’ risk estimates.
CONCLUSION: While the OLAP tool was rated understandable and acceptable, it was only of modest interest and did not change MSers’ prognostic estimates. The results suggest, however, that MSers had some idea regarding their prognosis and which factors were most important in this regard. Future work with OLAP should assess long-term prognostic estimates and clarify its usefulness for MSers and physicians facing treatment decisions.
One thought on “Prognostic risk estimates in MS”
I have heard 'patronising neurologists' say things like "Doesn't matter if you don't have DMT. You can still do very well"But sometimes treatment is unavailable or unaffordable. At least this helps patients to stay positive as long as their MS allows them to do so